Evidence map›Paper›PMID 29805693›Full record

ArticleOncology letters2018

Effect of CXCR4 silencing with shRNA on MAPK signaling in ovarian cancer.

Xiuli Wang, Hongying Wang, Xia Wei, Aixia Wang, Lina Wen, Li Wang, Qun Huang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. CXCL12 restricts tumor growth by suppressing the Ras, ERK1/2, c-Myc, and the immune checkpoint PD-L1 pathways.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Integrated Single-Cell RNA-seq and ATAC-seq Reveals Heterogeneous Differentiation of CD4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiuli WangDepartment of Obstetrics and Gynecology, Liaocheng People's Hospital of Shandong Province, Liaocheng, Shandong 252000, P.R. China.
Hongying WangDepartment of Obstetrics and Gynecology, Liaocheng People's Hospital of Shandong Province, Liaocheng, Shandong 252000, P.R. China.
Xia WeiDepartment of Obstetrics and Gynecology, Liaocheng People's Hospital of Shandong Province, Liaocheng, Shandong 252000, P.R. China.
Aixia WangDepartment of Obstetrics and Gynecology, Liaocheng People's Hospital of Shandong Province, Liaocheng, Shandong 252000, P.R. China.
Lina WenDepartment of Obstetrics and Gynecology, Liaocheng People's Hospital of Shandong Province, Liaocheng, Shandong 252000, P.R. China.
Li WangDepartment of Obstetrics and Gynecology, Liaocheng People's Hospital of Shandong Province, Liaocheng, Shandong 252000, P.R. China.
Qun HuangDepartment of Obstetrics and Gynecology, Liaocheng People's Hospital of Shandong Province, Liaocheng, Shandong 252000, P.R. China.
Liaocheng People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous study demonstrated that short hairpin RNA (shRNA) targeting of C-X-C chemokine receptor type 4 (

Indexed as

C-X-C chemokine receptor type 4mitogen-activated protein kinase pathwayovarian cancerRNA interference

Identifiers

PMID29805693
PMCPMC5958742
OpenAlexW2800880984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.